The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial

@article{Eichhorn2001TheCP,
  title={The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial},
  author={Eric J. Eichhorn and Michael R. Bristow},
  journal={Current Controlled Trials in Cardiovascular Medicine},
  year={2001},
  volume={2},
  pages={20 - 23}
}
Previous trials (Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure [MERIT-HF], Cardiac Insufficiency Bisoprolol Study [CIBIS] II) have demonstrated a mortality benefit of beta-adrenergic blockade in patients with mild to moderate heart failure. The recent Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial has extended these results to a more advanced patient population. This trial did not, however, include patients who could not reach compensation… CONTINUE READING

2 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Previous trials ( Metoprolol CR / XL Randomised Intervention Trial in Congestive Heart Failure [ MERIT - HF ] , Cardiac Insufficiency Bisoprolol Study [ CIBIS ] II ) have demonstrated a mortality benefit of beta - adrenergic blockade in patients with mild to moderate heart failure .
Previous trials ( Metoprolol CR / XL Randomised Intervention Trial in Congestive Heart Failure [ MERIT - HF ] , Cardiac Insufficiency Bisoprolol Study [ CIBIS ] II ) have demonstrated a mortality benefit of beta - adrenergic blockade in patients with mild to moderate heart failure .
All Topics